EN DE
Watch Coya Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Coya Therapeutics, Inc. (COYA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Coya Therapeutics, Inc. stock $1.56, price $2.99, that is 48.0% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CT Coya Therapeutics, Inc. logo Thin data Nov 6, 2026

Coya Therapeutics, Inc.

COYA · US
Very expensive, weak quality

Our calculation puts a fair price 48% below what the stock costs today.

Revenue last quarter +49% vs. a year ago.
Quality 43/100
Mixed Growth (revenue YoY +123.6 %/yr in USD)
Mixed vs. peers (3/7)
Fair value $1.56 · Strongly overvalued
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
⚠ Dilution
Watch Coya Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$10.19 $2.81 Fair Value $1.56 Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

46‑month range $2.81 – $10.19 · fair‑value band $1.03 – $1.95 · the $2.99 price screens above the $1.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Coya Therapeutics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Coya Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs).

Show moreShow less

Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease.

In addition, its pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101.

It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas.

Stock analysis

Coya Therapeutics, Inc. (COYA) currently trades at $2.99, while our model-based Fair Value estimate is $1.56, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.03 (bear) to $1.95 (bull), the price of $2.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Coya Therapeutics, Inc. Common Stock reported revenue of $7.9M in FY2025 versus $0 in FY2021. Reported net income was −$21.2M in FY2025.

Key figures

Market cap $70.1M Micro · P/S ratio 8.22 · EPS (TTM) $−1.07 · Return on equity −60.5% · Return on assets (EBIT) −63.4% (5-year average) · Operating margin −2,890% · Revenue (TTM) $8.0M · Revenue growth (YoY) +49.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 54% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −48%, COYA screens richer than that median.

Fair Value models

Bear $1.03 Fair Value $1.56 Bull $1.95
Price $2.99 · Downside -48.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $1.21 $1.83 $2.29 52
All 1 models by family
Asset-Based
NCAV (Graham) $1.21 $1.83 $2.29 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 42
How calm the share price moves, does not count
Price momentum 11
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

COYA screens overvalued: fair value 48% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Coya Therapeutics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −48.0% · Above median
Profitability
Return on assets −42.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 49.0% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.63× · Cheaper than median
P/S (12 months) 8.75× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs COYA
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs COYA
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs COYA
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs COYA
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs COYA
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs COYA
argenx SE ARGX $927.21 $908.40 −2% vs COYA
CSL Limited CSL A$200.77 A$183.04 −9% vs COYA
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs COYA
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs COYA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Coya Therapeutics, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Coya Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/COYA

Frequently asked questions

Is Coya Therapeutics, Inc. (COYA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $1.56 versus a price of $2.99, about 48% lower (overvalued).
What is the fair value of COYA?
Our model-based fair value for Coya Therapeutics, Inc. is $1.56 (as of Nov 6, 2026), built from audited fundamentals. The current price: $2.99.
What is the quality score of COYA?
Coya Therapeutics, Inc. has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Coya Therapeutics, Inc. (COYA)?
Our model-based price target is the fair value of $1.56 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $1.03, optimistic scenario $1.95. It is a calculation from audited fundamentals, not an analyst target.
What is the Coya Therapeutics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $1.56, about 48% lower versus a price of $2.99 (overvalued). Cautious scenario $1.03, optimistic scenario $1.95. The calculation is refreshed regularly with new filings.
What is the revenue of Coya Therapeutics, Inc. (COYA)?
Coya Therapeutics, Inc. reported trailing-twelve-month revenue of about $8.0M (latest available figure, as of Nov 6, 2026).
What is the intrinsic value of Coya Therapeutics, Inc. (COYA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Coya Therapeutics, Inc. it is $1.56 per share (as of Nov 6, 2026), against a price of $2.99. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Coya Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 6, 2026, COYA trades above its calculated fair value: price $2.99, fair value $1.56, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COYA?
No. The price is what the market pays today ($2.99); the fair value is what the company's own numbers justify ($1.56). For Coya Therapeutics, Inc. the two are $1.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Coya Therapeutics, Inc. Common Stock worth?
The market values Coya Therapeutics, Inc. at about $70.1M (market capitalisation, as of Nov 6, 2026). Per share that is $2.99; our models calculate a fair value of $1.56 per share.
What do the bullish and bearish scenarios say about COYA?
Our models span a range for Coya Therapeutics, Inc.: cautious scenario $1.03, base $1.56, optimistic $1.95 per share (as of Nov 6, 2026, price $2.99). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Coya Therapeutics, Inc. (COYA)?
Balance-sheet figures for Coya Therapeutics, Inc. (as of Nov 6, 2026): return on equity −60.5%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is COYA from its 52-week high?
Coya Therapeutics, Inc. trades at $2.99, about 54% below its 52-week high of $6.51 and 6% above the low of $2.81 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.56 is for.
Which stocks are comparable to Coya Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Coya Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Nov 6, 2026: price $2.99, calculated fair value $1.56 (−48%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COYA calculated?
We run Coya Therapeutics, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.56 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Coya Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Coya Therapeutics, Inc. (COYA)?
The closing price on Nov 6, 2026 was $2.99. Our model-based fair value is $1.56, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Coya Therapeutics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($1.95). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.03 to $1.95) leaves room in how you read the outcome.

Key figures of Coya Therapeutics, Inc.

How large is the market capitalisation of Coya Therapeutics, Inc. (COYA)?
The market capitalisation of Coya Therapeutics, Inc. is $70.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Coya Therapeutics, Inc. (COYA)?
The price-to-sales ratio of Coya Therapeutics, Inc. is 8.22 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Coya Therapeutics, Inc. (COYA)?
Earnings per share at Coya Therapeutics, Inc. are $−1.07. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Coya Therapeutics, Inc. (COYA)?
The return on equity (ROE) of Coya Therapeutics, Inc. is −60.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Coya Therapeutics, Inc. (COYA)?
On an EBIT basis the return on assets of Coya Therapeutics, Inc. is −63.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Coya Therapeutics, Inc. (COYA)?
The operating margin of Coya Therapeutics, Inc. is −2,890% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Coya Therapeutics, Inc. (COYA)?
Revenue at Coya Therapeutics, Inc. is growing +49.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Coya Therapeutics, Inc. (COYA) generate?
The free cash flow of Coya Therapeutics, Inc. is −$10.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Coya Therapeutics, Inc. (COYA) hold?
Coya Therapeutics, Inc. holds more cash than debt, $46.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Coya Therapeutics, Inc. Common Stock in the live analysis

One click puts Coya Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.